These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34477213)

  • 1. Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine.
    Domitrz I; Sławek J; Słowik A; Boczarska-Jedynak M; Stępień A; Rejdak K; Gierczyński J; Rożniecki J
    Neurol Neurochir Pol; 2022; 56(1):39-47. PubMed ID: 34477213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
    J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum neurotoxin--a therapy in migraine].
    Tajti J; Szok D; Tuka B; Csáti A; Kuris A; Majláth Z; Lukács M; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):77-82. PubMed ID: 23136725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.
    Montisano DA; Giossi R; Canella M; Altamura C; Marcosano M; Vernieri F; Raggi A; Grazzi L
    Toxins (Basel); 2024 Apr; 16(4):. PubMed ID: 38668603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
    Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
    Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model.
    Reducha PV; Bömers JP; Edvinsson L; Haanes KA
    Headache; 2024 Jun; 64(6):652-662. PubMed ID: 38700141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions.
    Raciti L; Raciti G; Militi D; Casella C; Calabrò RS
    J Integr Neurosci; 2022 Aug; 21(5):141. PubMed ID: 36137961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin in the Treatment of Headache.
    Becker WJ
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33348571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Pellesi L; Do TP; Ashina H; Ashina M; Burstein R
    Headache; 2020 Jun; 60(6):1056-1065. PubMed ID: 32437038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment.
    González-Quintanilla V; Evers S; Pascual J
    Handb Clin Neurol; 2024; 199():87-106. PubMed ID: 38307674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
    Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
    Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity.
    Onan D; Bentivegna E; Martelletti P
    Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.
    Durham PL; Masterson CG
    Headache; 2013 Jan; 53(1):67-80. PubMed ID: 23095108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.
    Ceccardi G; Schiano di Cola F; Caratozzolo S; Di Pasquale M; Bolchini M; Padovani A; Rao R
    Toxins (Basel); 2023 Nov; 15(12):. PubMed ID: 38133181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA injection in the treatment of chronic migraine.
    Wang YF
    Prog Brain Res; 2020; 255():171-206. PubMed ID: 33008506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy.
    Santoro A; Copetti M; Miscio AM; Leone MA; Fontana A
    Neurol Sci; 2020 Jul; 41(7):1809-1820. PubMed ID: 32052306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.